Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | RARB | P10826 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RARA | P10276 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894410 | 0.99 | KMT2A (0.59) | KMT2ARARBALDH1A1MEN1RARA | |
| SCHEMBL14392781 | 0.95 | KMT2A (0.62) | KMT2ARARBALDH1A1MEN1RARA | |
| SCHEMBL11105772 | 0.85 | RARB (0.57) | KMT2ARARBALDH1A1MEN1RARA | |
| SCHEMBL7408363 | 0.84 | CYP19A1 (0.47) | KMT2ATSHRTBXA2R | |
| SCHEMBL27846645 | 0.82 | FABP4 (0.47) | — | |
| SCHEMBL28367131 | 0.82 | ALDH1A1 (0.55) | KMT2AALDH1A1MEN1MAPTTBXA2R | |
| SCHEMBL10680125 | 0.81 | L3MBTL1 (0.55) | KMT2AALDH1A1MEN1PTPN1 | |
| SCHEMBL7698661 | 0.81 | HDAC3 (0.56) | TSHRPTPN1 | |
| SCHEMBL7399025 | 0.80 | KMT2A (0.43) | KMT2APTPN1TBXA2R | |
| SCHEMBL16051464 | 0.79 | THRA (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083471-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same | FAS SECURED CREDITORS HOLDCO, LLC | 2012-04-05 | — | — | US | disclosed |
| EP-2303013-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, METHODS OF USE FOR SAME, AND METHODS FOR PREPARING SAME | Fasgen, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010005922-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, METHODS OF USE FOR SAME, AND METHODS FOR PREPARING SAME | FASGEN, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083471-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same | LCAT, DGAT2, SOAT2 | KMT2A 1502/4885RARB 4560/4885ALDH1A1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.